Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done
by PET-CT scan after 6 weeks.
In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding
patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of
response assessment at each time-point).
Phase:
Phase 2
Details
Lead Sponsor:
Rabin Medical Center Soroka University Medical Center